Skip to main content

Verastem, Inc. (VSTM)

NASDAQ: VSTM · IEX Real-Time Price · USD
2.75
-0.01 (-0.36%)
After-hours:Oct 15, 2021 5:58 PM EDT
2.76
0.01 (0.36%)
At close: Oct 15, 4:00 PM
Market Cap499.80M
Revenue (ttm)80.66M
Net Income (ttm)-38.66M
Shares Out171.99M
EPS (ttm)-0.23
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,197,440
Open2.82
Previous Close2.75
Day's Range2.74 - 2.82
52-Week Range1.14 - 4.93
Beta0.78
AnalystsBuy
Price Target6.25 (+126.4%)
Est. Earnings DateNov 9, 2021

About VSTM

Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing medicines to enhance the life of cancer patients. Its product in development include VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibitor that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactin...

IndustryBiotechnology
IPO DateJan 27, 2012
CEOBrian Stuglik
Employees48
Stock ExchangeNASDAQ
Ticker SymbolVSTM
Full Company Profile

Financial Performance

In 2020, Verastem's revenue was $88.52 million, an increase of 407.08% compared to the previous year's $17.46 million. Losses were -$67.73 million, -54.61% less than in 2019.

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for Verastem stock is "Buy." The 12-month stock price forecast is 6.25, which is an increase of 126.45% from the latest price.

Price Target
$6.25
(126.45% upside)
Analyst Consensus: Buy

News

3 Biotech Stocks That Could Make You Filthy Rich

These three low-priced cancer stocks could be grossly undervalued.

Other symbols:ADAPCRVS
2 weeks ago - The Motley Fool

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of options to purchase 450,...

3 weeks ago - Business Wire

Top Penny Stocks To Buy The Dip According To Analysts In September

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:DRMANMTRZYNE
3 weeks ago - PennyStocks

Verastem Oncology Appoints Louis J. Denis, M.D.

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the appointment of Louis J. Denis, M....

3 weeks ago - Business Wire

Why Verastem Stock Spiked Today

A clinical collaboration with biotech titan Amgen briefly lit a fire underneath Verastem's shares today.

3 weeks ago - The Motley Fool

Penny Biotech Stocks: 8 Things for Verastem Investors to Know as VSTM Stock Shoots Higher

Verastem (VSTM) stock is on the rise Monday morning following an announcement from the company concerning a deal with Amgen (AMGN). The post Penny Biotech Stocks: 8 Things for Verastem Investors to Know...

3 weeks ago - InvestorPlace

Verastem Oncology and Amgen Partner to Evaluate VS-6766 in Combination with LUMAKRASTM (Sotorasib) in Patients with K...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced a clinical collaboration agreemen...

3 weeks ago - Business Wire

Verastem Shares Are Trading Higher On Encouraging Combo Therapy Data At ESMO Presentation

Verastem Oncology Inc (NASDAQ: VSTM) stock is trading higher after updated data from the ongoing Phase 1/2 FRAME study.  The investigator-sponsored study is investigating VS-6766, Verastem's RAF/MEK inh...

3 weeks ago - Benzinga

Verastem Oncology Announces Updated Investigator-Sponsored Phase 1/2 FRAME Study Data of VS-6766 with Defactinib in L...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced a mini oral presentation highlighting...

3 weeks ago - Business Wire

Best Penny Stocks To Buy? 5 To Watch This Week With Biotech Catalysts

Penny stocks with important dates to know this week. The post Best Penny Stocks To Buy?

Other symbols:APRECAPRCFMSSPPI
3 weeks ago - PennyStocks

4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351%

These penny stocks have upcoming events you should know about. The post 4 Biotech Penny Stocks To Watch After EFTR Stock Jumps 351% appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other symbols:HEPALPTXNYMX
1 month ago - PennyStocks

Verastem Oncology to Present at Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that management will present vir...

1 month ago - Business Wire

These Reddit Penny Stocks Exploded Today, Are They On Your List?

These Reddit penny stocks popped off today, are they worth watching in 2021 The post These Reddit Penny Stocks Exploded Today, Are They On Your List? appeared first on Penny Stocks to Buy, Picks, News a...

Other symbols:NXEPETVSHIP
1 month ago - PennyStocks

Verastem Oncology Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three m...

2 months ago - Business Wire

Verastem Oncology Announces Updated Phase 1/2 FRAME Study Data in Low Grade Serous Ovarian Cancer Selected for a Mini...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that an abstract detailing updat...

2 months ago - Business Wire

Verastem Oncology Announces Conversion of Senior Notes Eliminating Substantially All Outstanding Debt

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that it has converted all of the...

2 months ago - Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase ...

3 months ago - Business Wire

Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of Directors

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to developing and commercializing new medicines for patients battling cancer, today announced the appointm...

3 months ago - Business Wire

2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin

These unloved cancer stocks should dramatically outperform Dogecoin over the long haul.

Other symbols:ADAP
3 months ago - The Motley Fool

Verastem (VSTM) Enters Overbought Territory

Verastem (VSTM) has moved higher as of late, but there could definitely be trouble on the horizon for this company.

4 months ago - Zacks Investment Research

These Penny Stocks Hit it Big Yesterday, Here's Why

Did these penny stocks slip by yesterday unnoticed? Here's 3 big gainers you may have missed The post These Penny Stocks Hit it Big Yesterday, Here's Why appeared first on Penny Stocks to Buy, Picks, Ne...

Other symbols:SBTELL
4 months ago - PennyStocks

Verastem Oncology to Present at the 2021 Jefferies Virtual Healthcare Conference

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced t...

4 months ago - Business Wire

Why Verastem Stock Is Crushing It Today

The biotech's experimental cancer treatment won an important regulatory designation today.

4 months ago - The Motley Fool

Verastem's VS-6766/Defactinib Combo Gets Breakthrough Therapy Tag For Ovarian Cancer; BTIG Upgrades Stock

The FDA has granted Breakthrough Therapy designation to Verastem Inc (NASDAQ: VSTM) for the combination of its investigational VS-6766, with defactinib, for recurrent low-grade serous ovarian cancer (LG...

4 months ago - Benzinga

Verastem Oncology Receives Breakthrough Therapy Designation for VS-6766 with Defactinib in Recurrent Low-Grade Serous...

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced th...

4 months ago - Business Wire